Associated Papers
Clinical Application of a Customized Gene Panel for Identifying Autism Spectrum Disorder-Associated Variants.
Greco V et al.
Medicina (kaunas, Lithuania), 2025
Altered cytoplasmic and nuclear ADP-ribosylation levels analyzed with an improved ADP-ribose binder are a prognostic factor in renal cell carcinoma.
Schraml P et al.
The Journal of Pathology. Clinical Research, 2023
Genomes for Kids: The Scope of Pathogenic Mutations in Pediatric Cancer Revealed by Comprehensive DNA and RNA Sequencing.
Newman S et al.
Cancer Discovery, 2021
Next-Generation Sequencing-Directed Therapy in Patients with Metastatic Breast Cancer in Routine Clinical Practice.
Bruzas S et al.
Cancers, 2021
Clinicopathologic and molecular analysis of embryonal rhabdomyosarcoma of the genitourinary tract: evidence for a distinct DICER1-associated subgroup.
Kommoss FKF et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc, 2021
Molecular profiling of soft-tissue sarcomas with FoundationOne® Heme identifies potential targets for sarcoma therapy: a single-centre experience.
Scheipl S et al.
Therapeutic Advances in Medical Oncology, 2021
Prolonged survival and response to tepotinib in a non-small-cell lung cancer patient with brain metastases harboring MET exon 14 mutation: a research report.
Roth KG et al.
Cold Spring Harbor Molecular Case Studies, 2020
Unexpected cancer-predisposition gene variants in Cowden syndrome and Bannayan-Riley-Ruvalcaba syndrome patients without underlying germline PTEN mutations.
Yehia L et al.
Plos Genetics, 2018
Germline mutations in candidate predisposition genes in individuals with cutaneous melanoma and at least two independent additional primary cancers.
Pritchard AL et al.
Plos One, 2018
Gastrointestinal malignancies harbor actionable MET exon 14 deletions.
Lee J et al.
Oncotarget, 2015
MET genetic abnormalities unreliable for patient selection for therapeutic intervention in oropharyngeal squamous cell carcinoma.
Lacroix L et al.
Plos One, 2014
Activating mutation in MET oncogene in familial colorectal cancer.
Neklason DW et al.
Bmc Cancer, 2011
The role of the c-Met pathway in lung cancer and the potential for targeted therapy.
Sattler M et al.
Therapeutic Advances in Medical Oncology, 2011
Coactivation of receptor tyrosine kinases in malignant mesothelioma as a rationale for combination targeted therapy.
Brevet M et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer, 2011
Expression and mutational analysis of MET in human solid cancers.
Ma PC et al.
Genes, Chromosomes & Cancer, 2008